相似文献
1
Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil.
J Clin Microbiol. 2003 Jul;41(7):3403-6. doi: 10.1128/JCM.41.7.3403-3406.2003.
2
Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium.
J Clin Microbiol. 2006 Nov;44(11):4189-92. doi: 10.1128/JCM.00796-06. Epub 2006 Sep 6.
3
Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia.
J Clin Microbiol. 2005 Sep;43(9):4826-9. doi: 10.1128/JCM.43.9.4826-4829.2005.
4
Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain.
Microb Drug Resist. 2014 Aug;20(4):259-63. doi: 10.1089/mdr.2013.0127. Epub 2013 Dec 11.
5
Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil.
Am J Infect Control. 2010 May;38(4):308-14. doi: 10.1016/j.ajic.2009.09.012. Epub 2010 Jan 31.
6
Clonal relatedness and resistance characteristics of OXA-24 and -58 producing carbapenem-resistant Acinetobacter baumannii isolates in Tehran, Iran.
J Appl Microbiol. 2019 Nov;127(5):1421-1429. doi: 10.1111/jam.14409. Epub 2019 Sep 10.
7
Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40.
Antimicrob Agents Chemother. 2006 Sep;50(9):2941-5. doi: 10.1128/AAC.00116-06.
8
Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain.
J Clin Microbiol. 2002 Dec;40(12):4741-3. doi: 10.1128/JCM.40.12.4741-4743.2002.
9
Nosocomial spread of OXA-58-positive carbapenem-resistant Acinetobacter baumannii isolates in a paediatric hospital in Greece.
Clin Microbiol Infect. 2006 Nov;12(11):1138-41. doi: 10.1111/j.1469-0691.2006.01537.x.
10
Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre.
J Med Microbiol. 2009 Nov;58(Pt 11):1499-1507. doi: 10.1099/jmm.0.012302-0. Epub 2009 Jul 9.
引用本文的文献
1
Carbapenem Resistance in : Mechanisms, Therapeutics, and Innovations.
Microorganisms. 2025 Jun 27;13(7):1501. doi: 10.3390/microorganisms13071501.
2
Genetic, antimicrobial resistance profile andmortality rates of Acinetobacter baumanniiinfection in Brazil: A systematic reviewMirian.
Narra J. 2022 Apr;2(1):e68. doi: 10.52225/narra.v2i1.68. Epub 2022 Apr 1.
3
A 7-Year Brazilian National Perspective on Plasmid-Mediated Carbapenem Resistance in Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex and the Impact of the Coronavirus Disease 2019 Pandemic on Their Occurrence.
Clin Infect Dis. 2023 Jul 5;77(Suppl 1):S29-S37. doi: 10.1093/cid/ciad260.
4
The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant .
Front Microbiol. 2022 Nov 22;13:1024702. doi: 10.3389/fmicb.2022.1024702. eCollection 2022.
5
The Role of Uniform Meropenem Usage in Clone Replacement.
Antibiotics (Basel). 2021 Jan 29;10(2):127. doi: 10.3390/antibiotics10020127.
6
The Experience of Implementing a National Antimicrobial Resistance Surveillance System in Brazil.
Front Public Health. 2021 Jan 14;8:575536. doi: 10.3389/fpubh.2020.575536. eCollection 2020.
7
Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.
Rev Soc Bras Med Trop. 2020 Nov 6;53:e20200248. doi: 10.1590/0037-8682-0248-2020. eCollection 2020.
8
Multidrug-resistant Acinetobacter baumannii: differential adherence to HEp-2 and A-549 cells.
Braz J Microbiol. 2020 Jun;51(2):657-664. doi: 10.1007/s42770-020-00252-x. Epub 2020 Mar 16.
9
Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru.
Emerg Microbes Infect. 2018 Jul 4;7(1):119. doi: 10.1038/s41426-018-0127-9.
10
Molecular characterization and clonal dynamics of nosocomial blaOXA-23 producing XDR Acinetobacter baumannii.
PLoS One. 2018 Jun 11;13(6):e0198643. doi: 10.1371/journal.pone.0198643. eCollection 2018.
本文引用的文献
1
ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii.
Int J Antimicrob Agents. 1993 Feb;2(2):81-7. doi: 10.1016/0924-8579(93)90045-7.
2
Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain.
J Clin Microbiol. 2002 Dec;40(12):4741-3. doi: 10.1128/JCM.40.12.4741-4743.2002.
3
Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support.
Curr Pharm Biotechnol. 2002 Jun;3(2):117-27. doi: 10.2174/1389201023378427.
4
The impact of carbapenemases on antimicrobial development and therapy.
Curr Opin Investig Drugs. 2002 Feb;3(2):218-24.
5
Chromosome-encoded class D beta-lactamase OXA-23 in Proteus mirabilis.
Antimicrob Agents Chemother. 2002 Jun;46(6):2004-6. doi: 10.1128/AAC.46.6.2004-2006.2002.
6
Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii.
Antimicrob Agents Chemother. 2001 Feb;45(2):583-8. doi: 10.1128/AAC.45.2.583-588.2001.
7
OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.
Antimicrob Agents Chemother. 2000 Jun;44(6):1556-61. doi: 10.1128/AAC.44.6.1556-1561.2000.
8
Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece.
J Clin Microbiol. 2000 Mar;38(3):1290-2. doi: 10.1128/JCM.38.3.1290-1292.2000.
9
Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92.
Antimicrob Agents Chemother. 2000 Jan;44(1):196-9. doi: 10.1128/AAC.44.1.196-199.2000.
10
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
Clin Infect Dis. 1999 May;28(5):1008-11. doi: 10.1086/514732.
Zotero 插件